EUVIMEDEUVIMED entdecken
VergleichsstudieNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis

Heng Xiang, Zhihua She, Liting Wang, Ye Peng, Lei Zhang, Chongqing Tan iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0337606 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Heng Xiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atezolizumab combined with either bevacizumab (atezo-beva) or cabozantinib (atezo-cabo) has been granted approval for the treatment of advanced hepatocellular carcinoma (HCC). Given the current uncertainty among physicians and patients regarding the optimal choice between these two strategies, it becomes imperative to conduct a cost-effectiveness analysis to compare their relative benefits.

Objective

Assessing the cost-effectiveness of atezo-beva compared to atezo-cabo in the treatment of advanced HCC.

Methods

Both the network treatment comparison and cost-effectiveness analysis included patients from the IMbrave150 and the COSMIC-312 phase 3 randomized clinical trials. The network treatment comparison which included 761 patients was carried out, and a cost-effectiveness analysis that included 487 patients was conducted by developing a Markov model, both between February and November 2020. The robustness of the model was assessed via one-way and probabilistic sensitivity analyses. life-years, quality-adjusted life-years (QALYs), overall costs, and incremental cost-effectiveness ratios (ICERs) were measured.

Results

Compared with the atezo-cabo group, atezo-beva group respectively increased 0.528 life years and 0.365 QALYs, with costs per patient increasing by $506,639, and the ICER was $1,388,052.054 per QALY. The one-way sensitivity analysis results indicated that the hazard ratios of OS and HR of PFS were the most sensitive factors in the model. In probabilistic sensitivity analysis, when the WTP threshold is $150,000 per QALY, the cost-effectiveness probabilities of the atezo-beva group and atezo-cabo group were 7.09% and 92.91% respectively.

Conclusions

Findings from this cost-effectiveness analysis suggested that, compared to atezo-cabo, atezo-beva brought better OS benefits to advanced HCC patients, but also brought higher economic burden, considering the willingness-to-pay threshold was $150 000 per QALY, atezo-beva was not considered cost-effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Effectiveness AnalysisCarcinoma, HepatocellularLiver NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsAnilidesPyridinesAngiogenesis InhibitorsQuality-Adjusted Life YearsMarkov ChainsProgression-Free SurvivalRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicHumansUnited StatesMaleFemaleMiddle AgedAged

Substanzen

atezolizumabBevacizumabcabozantinibAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsAnilidesPyridinesAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
  • Department of Pharmacy, the Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China.
  • Department of Nephrology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

ORCID-Profile: Chongqing Tan

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Xiang, H., She, Z., Wang, L., Peng, Y., Zhang, L., & Tan, C. (2025). Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis. PLOS One. https://doi.org/10.1371/journal.pone.0337606

Vancouver

Xiang H, She Z, Wang L, Peng Y, Zhang L, Tan C. Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis. PLOS One. 2025. doi:10.1371/journal.pone.0337606

BibTeX
@article{Xiang2025,
  author = {Xiang, Heng and She, Zhihua and Wang, Liting and Peng, Ye and Zhang, Lei and Tan, Chongqing},
  title = {Comparison of Atezolizumab plus Aevacizumab and Atezolizumab plus Aabozantinib for advanced hepatocellular carcinoma: A cost-effectiveness analysis},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0337606}
}
Kostenlos starten →